An experimental drug for metastatic pancreatic cancer has nearly doubled overall survival rates in a landmark Phase 3 clinical trial, raising hope for patients battling one of the deadliest and most resistant forms of cancer.
The findings, unveiled on Sunday, May 31st, at the American Society of Clinical Oncology (ASCO) annual meeting and simultaneously published in the New England Journal of Medicine, mark what many oncologists are calling a watershed moment in the history of pancreatic cancer treatment.
The Drug and Trial
The drug, daraxonrasib, is an oral targeted therapy developed to block RAS proteins — molecular switches that, when mutated, fuel the unchecked growth of cancer cells. Patients who received daraxonrasib in the global trial lived a median of 13.2 months, compared with just 6.7 months for those who received standard chemotherapy.
That gap of roughly six months may sound modest to the layperson, but within oncology it represents an extraordinary leap forward for a disease that has defied therapeutic progress for decades.
“I think many of us would consider this a big win,” said Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute. “The trial is trying to help people live as long as they can and actually live better with less side effects, less symptoms from the cancer, and that is a very big deal.”
The global Phase 3 trial enrolled 500 patients with metastatic pancreatic cancer who had already undergone at least one prior round of chemotherapy. These were patients running out of options and, for many, daraxonrasib proved transformative.
Trial participant Jim described his experience with cautious but renewed optimism after a tumour began responding to the treatment, recounting that the diagnosis “can set you back or it can push you forward.”
The Science Behind the Drug
The science behind the drug centres on the KRAS gene, long considered one of the most elusive targets in oncology. KRAS mutations are present in more than 90 percent of pancreatic cancer cases, and for years researchers referred to the gene as “undruggable.”
Daraxonrasib, developed by Revolution Medicines, appears to work across several common forms of those mutations including G12D, G12V, G12R, and Q61X which means it could be applicable to the vast majority of pancreatic cancer patients, regardless of the precise variant of the mutation.
The Burden of Pancreatic Cancer
Pancreatic cancer is expected to claim more than 52,000 lives in the United States this year alone. It is frequently diagnosed only after it has already spread beyond the pancreas, leaving patients with few viable treatment paths.
The overall five-year survival rate sits at a grim 13 percent, and for those with metastatic disease, fewer than one in ten survive beyond a year. Until now, chemotherapy remained the de facto standard of care even after initial treatment failed.
Side Effects and Management
As with any new therapy, side effects remain a concern. Skin-related reactions, including severe rashes and photosensitivity, are among the most commonly reported. However, oncologists are learning to manage these reactions through prophylactic measures including oral antibiotics, topical steroids, and strict sun-avoidance protocols. Notably, only a small proportion of trial participants discontinued treatment due to adverse effects, suggesting that for most patients, the benefits outweighed the discomfort.
Regulatory Pathway
The regulatory pathway for daraxonrasib has been advancing in parallel with the clinical evidence. The U.S. Food and Drug Administration granted the drug Breakthrough Therapy designation in June 2025 based on promising Phase 1 results. By October 2025, the FDA flagged it for accelerated review through its Commissioner’s National Priority Voucher programme. In May 2026, the agency issued a “safe to proceed” letter to expand access for additional patients while full approval is sought.
Daraxonrasib is not yet approved by the FDA for general use, but the latest Phase 3 results are expected to accelerate that process significantly. For the hundreds of thousands of patients and families confronting pancreatic cancer each year, the drug represents something that has been in short supply for a very long time, which is genuine hope.
